AlphaMark Advisors’s Zomedica Corp. ZOM Stock Holding History

AlphaMark Advisors’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100	Closed	–	–	600
2021 Q1	$0	Buy	+100	New	+$163	﹤0.01%	581

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

KFS

Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return

AlphaMark Advisors's ZOM Position: Q2 2021 in Review

AlphaMark Advisors sold out of Zomedica Corp. (ZOM) in Q2 2021, closing a stake of 100 shares.

AlphaMark Advisors first reported a position in ZOM in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 106 funds tracked by Wall St. Rank hold ZOM as of Q2 2021.

AlphaMark Advisors reported no remaining Zomedica Corp. position as of Q2 2021 after selling out during the quarter.
AlphaMark Advisors sold 100 Zomedica Corp. shares in Q2 2021.
AlphaMark Advisors first reported a position in Zomedica Corp. in Q1 2021 and held it in 1 quarter.
AlphaMark Advisors's Zomedica Corp. position peaked at $0 in Q1 2021.
106 funds tracked by Wall St. Rank held Zomedica Corp. as of Q2 2021.

Based on AlphaMark Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.